Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 2:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HER2 Negative Breast Cancer Clear all
Completed Phase 2 Interventional Results available

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

NCT00436566
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, gene expression analysis, reverse transcriptase-polymerase chain reaction, fluorophotometry, laboratory biomarker analysis, mass spectrometry, adjuvant therapy, quality-of-life assessment
Biological · Drug · Genetic + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Jun 25, 2026, 2:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

NCT01740427
View directory record Official record
Conditions
Breast Neoplasms
Interventions
PD-0332991, Letrozole, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
136
States / cities
Bellflower, California • Beverly Hills, California • Fullerton, California + 83 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Jun 25, 2026, 2:02 PM EDT
Completed Phase 2 Interventional Results available

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

NCT01268150
View directory record Official record
Conditions
Locally Recurrent, Metastatic Breast Cancer ( HER2 Negative)
Interventions
Eribulin mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Miami, Florida • Augusta, Georgia • Macon, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jun 25, 2026, 2:02 PM EDT
Completed Phase 1 Interventional Results available

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

NCT04081389
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Celecoxib, Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Paclitaxel, Recombinant Interferon Alfa-2b, Rintatolimod
Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2023 · Synced Jun 25, 2026, 2:02 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07248144, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
102
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 25, 2026, 2:02 PM EDT
Completed Phase 2 Interventional Results available

Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer

NCT01688609
View directory record Official record
Conditions
HER2-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
lapatinib ditosylate, paclitaxel, trastuzumab, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
20 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Jun 25, 2026, 2:02 PM EDT
Completed Phase 2 Interventional

Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer

NCT00148707
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
CT-2103 (Xyotax)
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Jun 25, 2026, 2:02 PM EDT
Terminated Phase 1 Interventional

A Study of SGN-STNV in Advanced Solid Tumors

NCT04665921
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
Interventions
SGN-STNV
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Jun 25, 2026, 2:02 PM EDT
Terminated Phase 1 Interventional

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

NCT04182516
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors
Interventions
NMS-03305293
Drug
Lead sponsor
Nerviano Medical Sciences
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 25, 2026, 2:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

NCT05898399
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
ART6043, Olaparib
Drug
Lead sponsor
Artios Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 25, 2026, 2:02 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

NCT05095207
View directory record Official record
Conditions
Breast Cancer, Metastasis
Interventions
Abemaciclib, Bicalutamide
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 25, 2026, 2:02 PM EDT
Active, not recruiting Not applicable Interventional

Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer

NCT05130840
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI, Lumbar puncture
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jun 25, 2026, 2:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

NCT04505826
View directory record Official record
Conditions
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
Interventions
OP-1250
Drug
Lead sponsor
Olema Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Deerfield Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jun 25, 2026, 2:02 PM EDT
Recruiting Phase 1 Interventional

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

NCT06488378
View directory record Official record
Conditions
Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
Interventions
Axatilimab, Olaparib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jun 25, 2026, 2:02 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer

NCT01272141
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Cancer of the Breast
Interventions
Lapatinib and Everolimus
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Jun 25, 2026, 2:02 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

NCT05683418
View directory record Official record
Conditions
HR+/HER2-negative Breast Cancer
Interventions
TOS-358, Fulvestrant, Palbociclib, Ribociclib
Drug
Lead sponsor
Totus Medicines
Industry
Eligibility
18 Years and older · Female only
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 25, 2026, 2:02 PM EDT
Terminated Phase 1Phase 2 Interventional

Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers

NCT00095862
View directory record Official record
Conditions
Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
allogeneic GM-CSF-secreting breast cancer vaccine, recombinant interferon alfa, cyclophosphamide
Biological · Drug
Lead sponsor
Wiseman Research Initiatives LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
3
States / cities
Glendale, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Jun 25, 2026, 2:02 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

NCT07318805
View directory record Official record
Conditions
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions
PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
9
States / cities
Duarte, California • Grand Rapids, Michigan • Conroe, Texas + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 25, 2026, 2:02 PM EDT
Terminated Phase 3 Interventional Results available

Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

NCT03786094
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Interventions
Eribulin, Balixafortide
Drug
Lead sponsor
Spexis AG
Industry
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
28
States / cities
Fresno, California • Los Angeles, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Jun 25, 2026, 2:02 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

NCT03393845
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, Fulvestrant
Drug
Lead sponsor
Nancy Chan, MD
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
5
States / cities
Lansing, Michigan • Omaha, Nebraska • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jun 25, 2026, 2:02 PM EDT
Recruiting Not applicable Interventional

Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer

NCT05677802
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Negative Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Medical Chart Review, Stress Management Therapy, Survey Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Cleveland, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jun 25, 2026, 2:02 PM EDT
Recruiting Phase 2 Interventional

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

NCT06176261
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
Interventions
Datopotamab Deruxtecan
Drug
Lead sponsor
Sarah Sammons, MD
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jun 25, 2026, 2:02 PM EDT
Recruiting Phase 1 Interventional

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775
View directory record Official record
Conditions
Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer
Interventions
BBO-10203, Trastuzumab, Fulvestrant, Ribociclib, FOLFOX, Bevacizumab
Drug
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Industry
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 25, 2026, 2:02 PM EDT
Not listed Phase 1 Interventional

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

NCT02626507
View directory record Official record
Conditions
Breast Cancer
Interventions
Gedatolisib, Faslodex, Palbociclib, Zoladex
Drug
Lead sponsor
Hoffman Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Los Angeles, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Jun 25, 2026, 2:02 PM EDT